Investigation of mast cell toll-like receptor 3 in CFS/ME & Systemic Mastocytosis using novel application of autoMACS..., 2017, Balinas et al

Andy · Dec 11, 2017

Full title - Investigation of mast cell toll-like receptor 3 in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Systemic Mastocytosis participants using the novel application of autoMACS magnetic separation and flow cytometry.

Abstract
BACKGROUND:
Viral infections and hypersensitivities are commonly reported by Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) patients. Mast Cells (MC) uniquely mediate type 1 hypersensitivities and resolve viral infections via toll-like receptor 3 (TLR3).

OBJECTIVE:
To characterise and compare mast cell progenitors (MCPs) in CFS/ME participants with a known MC disorder, Systemic mastocytosis (SM), and secondly, to investigate the role of MC TLR3 in CFS/ME participants following Polyinosinicolycytidylic acid (Poly I:C) stimulation.

METHODS:
A total of 11 International Consensus Criteria defined CFS/ME participants (40.42 ± 10.31), 9 World Health Organisation defined systemic mastocytosis (SM) participants (47.00 ± 10.37) and 12 healthy controls (HC) (36.36 ± 9.88) were included. Following autoMACS magnetic separation, CD117+/Lin-MCPs were stimulated with Poly I:C for 24hr. MCP purity (CD117 and Lin2), maturity (CD34 and FcεRI), interaction receptors and ligands (CD154 and HLA-DR), and SM-specific (CD2 and CD25) markers were measured using flow cytometry.

RESULTS:
There was a significant decrease in HLA-DR+/CD154- expression between CFS/ME and SM groups pre and post Poly I:C stimulation. There were no significant differences in maturity MCPs, CD154, and CD2/CD25 expression between groups pre and post Poly I:C stimulation.

CONCLUSION:
This pilot investigation provides a novel methodology to characterise MCPs in a rapid, inexpensive and less invasive fashion. We report a significant decrease in HLA-DR+/CD154- expression between CFS/ME and SM participants, and an observed increase in HLA-DR-/CD154+ expression post Poly I:C stimulation in CFS/ME participants. Peripheral MCPs may be present in CFS/ME pathophysiology, however further investigation is required to determine their immunological role.
Click to expand...

https://www.ncbi.nlm.nih.gov/pubmed/29223146

Snow Leopard · Dec 11, 2017

Listing seems recent, DOI doesn't work yet.

I don't understand how TLR3 ties into the results they've reported.

Jonathan Edwards · Dec 11, 2017

The abstract is confusing. It seems that they found evidence that PWME do not have systemic mastocytosis - which is not very surprising. There is no comment about the comparison between ME and controls.

Log in or Sign up

Investigation of mast cell toll-like receptor 3 in CFS/ME & Systemic Mastocytosis using novel application of autoMACS..., 2017, Balinas et al

Andy Senior Member (Voting Rights)

Snow Leopard Senior Member (Voting Rights)

Jonathan Edwards Senior Member (Voting Rights)

Share This Page

Log in or Sign up

Investigation of mast cell toll-like receptor 3 in CFS/ME & Systemic Mastocytosis using novel application of autoMACS..., 2017, Balinas et al

Andy Senior Member (Voting Rights)

Snow Leopard Senior Member (Voting Rights)

Jonathan Edwards Senior Member (Voting Rights)

Share This Page

Useful Searches